Octagon Capital Advisors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001839435

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 26 positions · Total reported value $750.61M · Top-10 concentration 82.5% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 65.5% · 2 new · 14 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -23.3% · vs SPY -25.4% · Prev Value $1.11B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -9.9% · vs SPY -12.0% · Latest Value $750.61M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Octagon Capital Advisors LP disclosed 26 equity positions with a combined reported value of $750.61M. The filing implies a focused portfolio: its ten largest positions account for 82.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were DNTH ($148.51M), ABVX ($98.33M), DFTX ($95.57M). By sector, the heaviest allocations are Health Care 99.6%, Other 0.4%.

Versus the prior quarter, Octagon Capital Advisors LP opened 2 new positions, trimmed 14 and fully exited 3, a turnover rate of 65.5% of positions. The portfolio's overlap with the prior quarter was 83% of names.

The largest new positions opened in Q3 2026 were VRDN ($33.15M), TNGX ($15.72M).

Of the 3 positions fully exited versus the prior quarter, the largest were ALMS ($79.66M), SMMT ($18.21M), CNTX ($1.69M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • VRDN VIRIDIAN THERAPEUTICS INC · $33.15M
  • TNGX TANGO THERAPEUTICS INC · $15.72M

Fully Exited (vs previous quarter)

  • ALMS ALUMIS INC · prev qtr: $79.66M
  • SMMT SUMMIT THERAPEUTICS INC · prev qtr: $18.21M
  • CNTX CONTEXT THERAPEUTICS INC · prev qtr: $1.69M

Insider Transactions (Form 4)

Latest Octagon Capital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Octagon Capital Advisors LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 26 US equity positions with a combined value of $750.61M. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-118554 (status: Approved), registered 2020-04-27
  • Regulatory AUM (Form ADV): $1.18B as of 2026-03-20
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 1 hedge funds
  • Website: octagoninvestments.com

Portfolio Structure

  • 26 positions · $750.61M reported value (Q3 2026)
  • Top 10 holdings = 82.5% of reported value
  • Largest position: DNTH (DIANTHUS THERAPEUTICS INC) at 19.8%
  • Average position size: $28.87M

Sector Tilt

  • Health Care 99.6%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 2 new, 1 added, 14 reduced, 3 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is overweight Health Care (100% of top-10 holdings), with a modestly bullish tilt (increased weights on 4/10 top holdings, including new positions). Reduced exposure to 3 biotech names (DNTH, DFTX, KYMR) but added 2 new ones (VRDN, TNGX), suggesting selective optimism in biotech with a focus on clinical-stage therapeutics. 2. Key moves: - Added: AVBP (+8.6% shares, +2.48% weight), VRDN (new, 4.42%), TNGX (new, 2.09%). - Reduced: DNTH (-8.4% shares, +3.65% weight), DFTX (-14.9% shares, +0.26% weight), KYMR (-33.9% shares, -0.14% weight). - Held: ABVX, COGT, TSHA, IRON (no share changes, weight fluctuations due to price). 3. Portfolio structure: Highly active, concentrated in biotech/Health Care (100% of top-10), with high risk appetite (small-cap, clinical-stage names). No passive holdings; benchmark is unverified. 4. Per-holding one-liner: - DNTH: Dianthus Therapeutics (unverified, likely biotech). - ABVX: Abivax SA (unverified, likely biotech). - DFTX: Definium Therapeutics (unverified, likely biotech). - COGT: Cogent Biosciences (unverified, likely biotech). - AVBP: Arrivent Biopharma (unverified, likely biotech). - TSHA: Taysha Gene Therapies (unverified, likely gene therapy). - VRDN: Viridian Therapeutics (unverified, likely biotech). - KYMR: Kymera Therapeutics (unverified, likely biotech). - IRON: Disc Medicine (unverified, likely biotech). - TNGX: Tango Therapeutics (unverified, likely biotech). 5. Style summary: Concentrated, high-conviction biotech fund with selective new bets and trimmed exposure underperforming names.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 11:24

Sector Allocation

Health Care 99.6%
Other 0.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.69M $148.51M 19.79%
19.79%
Reduce
2 993.00K $98.33M 13.10%
13.10%
Hold
3 2.51M $95.57M 12.73%
12.73%
Reduce
4 2.35M $75.25M 10.03%
10.03%
Hold
5 2.14M $64.84M 8.64%
8.64%
Add
6 9.69M $47.21M 6.29%
6.29%
Hold
7 2.41M $33.15M 4.42%
4.42%
New
8 205.00K $22.92M 3.05%
3.05%
Reduce
9 270.00K $17.67M 2.35%
2.35%
Hold
10 630.00K $15.72M 2.09%
2.09%
New
11 420.00K $15.62M 2.08%
2.08%
Reduce
12 934.72K $14.96M 1.99%
1.99%
Hold
13 169.45K $14.48M 1.93%
1.93%
Reduce
14 713.00K $13.88M 1.85%
1.85%
Reduce
15 10.28M $13.87M 1.85%
1.85%
Hold
16 720.00K $10.56M 1.41%
1.41%
Reduce
17 1.30M $9.22M 1.23%
1.23%
Reduce
18 249.00K $7.90M 1.05%
1.05%
Reduce
19 954.42K $7.00M 0.93%
0.93%
Hold
20 574.20K $6.75M 0.90%
0.90%
Hold
21 599.90K $4.60M 0.61%
0.61%
Reduce
22 315.00K $4.51M 0.60%
0.60%
Hold
23 100.00K $2.97M 0.40%
0.40%
Reduce
24 430.00K $2.69M 0.36%
0.36%
Reduce
25 275.00K $1.29M 0.17%
0.17%
Reduce
26 96.88K $1.15M 0.15%
0.15%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 31% of its Top-10 each quarter and backtests at F1 70% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 70% · recall 70% · F1 70% · avg rank error 2.9 · Top-10 turnover 31%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 40% 40% 40% APLS · CBAY · VRNA · INSM · RCUS · BBIO · CLDX · ALPN · ROIV · CNTA ALPN · DNTH · VRNA · DYN · AVBP · INSM · CNTA · EYPT · OCUL · GPCR
2024-Q2 80% 80% 80% ALPN · DNTH · DYN · VRNA · AVBP · INSM · CNTA · GPCR · EYPT · OCUL DNTH · GPCR · DYN · AVBP · VRNA · CRBP · CNTA · BBIO · INSM · OCUL
2024-Q3 70% 70% 70% DNTH · GPCR · DYN · AVBP · VRNA · CRBP · CNTA · BBIO · OCUL · MNMD APLS · VRNA · GPCR · DNTH · AVBP · CNTA · NUVB · CRBP · OCUL · VRDN
2024-Q4 60% 60% 60% APLS · GPCR · VRNA · DNTH · AVBP · CNTA · NUVB · CRBP · OCUL · VRDN APLS · AVBP · DNTH · VRNA · NUVB · COGT · SRRK · MNMD · OCUL · TSHA
2025-Q1 60% 60% 60% APLS · AVBP · DNTH · NUVB · COGT · VRNA · MNMD · SRRK · OCUL · TSHA NUVBWS · APLS · DNTH · AVBP · TRVI · GOSS · OCUL · MNMD · COGT · KALV
2025-Q2 70% 70% 70% NUVBWS · APLS · DNTH · AVBP · GOSS · TRVI · COGT · OCUL · MNMD · TSHA DNTH · AVBP · VRNA · TSHA · SPRY · GOSS · OCUL · MRUS · TRVI · COGT
2025-Q3 70% 70% 70% DNTH · AVBP · VRNA · TSHA · SPRY · GOSS · OCUL · ATYR · MRUS · TRVI ABVX · DNTH · GOSS · COGT · AVBP · OCUL · TSHA · MRUS · TRVI · MNMD
2025-Q4 90% 90% 90% ABVX · DNTH · GOSS · COGT · AVBP · OCUL · TSHA · MRUS · TRVI · MNMD ABVX · DNTH · COGT · TSHA · GOSS · KYMR · AVBP · TRVI · OCUL · MNMD
2026-Q1 60% 60% 60% DNTH · ABVX · COGT · TSHA · KYMR · GOSS · AVBP · TRVI · OCUL · MNMD DNTH · COGT · ABVX · ALMS · DFTX · AVBP · TSHA · KYMR · MIRM · BIOA
2026-Q2 100% 100% 100% DNTH · COGT · ABVX · ALMS · DFTX · AVBP · TSHA · KYMR · MIRM · BIOA DNTH · DFTX · ABVX · COGT · ALMS · AVBP · TSHA · BIOA · MIRM · KYMR
2026-Q3 ★ 70% 70% 70% DNTH · DFTX · ABVX · COGT · ALMS · AVBP · TSHA · BIOA · MIRM · KYMR DNTH · ABVX · DFTX · COGT · AVBP · TSHA · VRDN · KYMR · IRON · TNGX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings3 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-38.51%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return-21.50%vs benchmark
Barra annualised vol60.3%Model estimate
Realised vol101.3%Annualised in window
Weighted beta1.34Raw exposure
Factor / specific risk43% / 57%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)58.270.282.394.4106.510-0110-2311-16Octagon Capital Advisors LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-38.51%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return-21.50%Portfolio − benchmark
Arithmetic return sum-41.08%Difference vs compounded is the cross term
Weighted raw beta1.34Weighted holding betas
Realised volatility (annualised)101.31%Daily returns in window
Barra model volatility (annualised)60.34%Factor + specific
Factor share of variance42.9%Barra factors
Specific share of variance57.1%Stock residuals
Reported value$127.8M13F long US equity

2. Return attribution

The -41.08% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -7.58% -18.4%
Momentum & Growth 3 -6.38% -15.5%
Volatility & Tail Risk 7 -3.42% -8.3%
Industry 12 +6.98% 17.0%
Specific 1 -30.69% -74.7%
Return attribution (style + industry, %)-14.3-7.1+0.0+7.1+14.3Amihud Illiquidity-1.23Growth-1.63Kurtosis+1.86Beta+2.20Skewness+2.36Leverage (Downside Vol)-2.66Non-linear Size+3.10Size+3.23Momentum-5.11Mid Cap-5.17Health Care+6.98Residual Volatility+7.21Turnover-7.68Historical Volatility-13.23
Factor Type Exposure Factor return Contribution Share of |return|
Residual Volatility Style +2.19 +3.29% +7.21% 17.5%
Health Care Industry +1.00 +6.98% +6.98% 17.0%
Size Style -1.66 -1.95% +3.23% 7.9%
Non-linear Size Style +3.07 +1.01% +3.10% 7.5%
Skewness Style -0.54 -4.39% +2.36% 5.8%
Beta Style +0.50 +4.44% +2.20% 5.3%
Kurtosis Style +0.25 +7.51% +1.86% 4.5%
Short-term Reversal Style +0.41 +0.87% +0.36% 0.9%
Liquidity Style +0.46 +0.36% +0.17% 0.4%
Max Drawdown Style +0.65 -1.76% -1.15% -2.8%
Amihud Illiquidity Style +2.75 -0.45% -1.23% -3.0%
Growth Style -0.93 +1.75% -1.63% -4.0%
Leverage (Downside Vol) Style +1.55 -1.71% -2.66% -6.5%
Momentum Style +1.28 -4.00% -5.11% -12.4%
Mid Cap Style +2.67 -1.94% -5.17% -12.6%
Turnover Style +1.60 -4.80% -7.68% -18.7%
Historical Volatility Style +0.95 -14.00% -13.23% -32.2%
Specific Specific — — -30.69% -74.7%

3. Risk attribution

Annualised volatility is 60.34%; factor risk explains 42.9% of variance and specific risk 57.1%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-61.6-30.8+0.0+30.8+61.6Growth-1.18Momentum+1.52Amihud Illiquidity+1.71Turnover+1.78Non-linear Size+1.97Max Drawdown+2.07Beta+2.69Size+3.31Historical Volatility+4.17Leverage (Downside Vol)+5.11Residual Volatility+6.15Health Care+6.91Mid Cap+7.04Specific+57.08
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 57.1% +34.44% 34.4%
Mid Cap Style +2.67 7.0% +4.25% 4.2%
Health Care Industry +1.00 6.9% +4.17% 4.2%
Residual Volatility Style +2.19 6.2% +3.71% 3.7%
Leverage (Downside Vol) Style +1.55 5.1% +3.08% 3.1%
Historical Volatility Style +0.95 4.2% +2.52% 2.5%
Size Style -1.66 3.3% +2.00% 2.0%
Beta Style +0.50 2.7% +1.62% 1.6%
Max Drawdown Style +0.65 2.1% +1.25% 1.2%
Non-linear Size Style +3.07 2.0% +1.19% 1.2%
Turnover Style +1.60 1.8% +1.08% 1.1%
Amihud Illiquidity Style +2.75 1.7% +1.03% 1.0%
Momentum Style +1.28 1.5% +0.92% 0.9%
Liquidity Style +0.46 0.5% +0.29% 0.3%
Kurtosis Style +0.25 -0.3% -0.17% -0.2%
Skewness Style -0.54 -0.6% -0.38% -0.4%
Growth Style -0.93 -1.2% -0.71% -0.7%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.1-0.70.72.13.5Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.66 +2.10 -3.76
Non-linear Size +3.07 +1.68 +1.39
Mid Cap +2.67 +0.13 +2.54
Beta +0.49 +1.29 -0.80
Momentum +1.28 +0.72 +0.56
Short-term Reversal +0.41 -0.64 +1.06
Residual Volatility +2.19 -0.40 +2.59
Historical Volatility +0.94 +0.86 +0.08
Liquidity +0.46 +0.11 +0.35
Amihud Illiquidity +2.75 +1.16 +1.60
Turnover +1.60 +0.21 +1.39
Growth -0.93 +0.58 -1.52
Leverage (Downside Vol) +1.55 +0.14 +1.41
Skewness -0.54 +0.24 -0.78
Kurtosis +0.25 +0.21 +0.03
Max Drawdown +0.65 -0.08 +0.73

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -37.91% +8.29% +24.98% -0.80% -45.39% -38.05%
Total +23.98% +15.04% -61.23% -22.21%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
AVBP ARRIVENT BIOPHARMA INC Health Care 50.75% -61.82% -31.37% Add
TSHA TAYSHA GENE THERAPIES INC Health Care 36.95% -16.63% -6.14% Hold
TNGX TANGO THERAPEUTICS INC Health Care 12.30% -3.13% -0.39% New
Contribution rank Symbol Sector Weight Return Contribution
1 TNGX Health Care 12.30% -3.13% -0.39%
2 TSHA Health Care 36.95% -16.63% -6.14%
3 AVBP Health Care 50.75% -61.82% -31.37%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -38.51%, versus -17.01% for the QQQ synthetic benchmark — an excess of -21.50%.
  2. Return attribution: the largest positive style/industry contributions came from Residual Volatility +7.21%, Health Care +6.98%, Size +3.23%; the largest drags came from Historical Volatility -13.23%, Turnover -7.68%, Mid Cap -5.17%. Specific (stock-level) return contributed -30.69%.
  3. Risk attribution: Barra model volatility is 60.34% annualised; factor risk explains 43% of variance and specific risk 57%. The largest factor risk sources are Mid Cap 7.0%, Health Care 6.9%, Residual Volatility 6.2%.
  4. Style tilt: size -1.66, momentum +1.28, volatility +0.94, liquidity +0.46; the weighted raw beta is 1.34. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.04% and interaction -61.23%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Octagon Capital Advisors LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Octagon Capital Advisors LP reported 26 equity positions worth $750.61M in aggregate; its largest disclosed positions were DNTH ($148.51M), ABVX ($98.33M), DFTX ($95.57M).

How large is Octagon Capital Advisors LP's portfolio?

Octagon Capital Advisors LP reported $750.61M of long equity holdings across 26 positions as of 2026-Q3. Top-10 holdings account for 82.5% of reported value.

What is Octagon Capital Advisors LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/octagon-capital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →